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Abstract: POT1 is the single stranded telomeric overhang binding protein, and is part of the shelterin complex, a group of
six proteins essential for proper telomere function. The reduction or abrogation of POT1 DNA binding activity in
mammalian cells results in telomere elongation, or activation of the ATR DNA damage response at telomeres. Therefore,
overhang binding represents the functionally relevant activity of POT1. To better understand the roles of POT1, we sought
to isolate proteins that interact with the DNA binding domain of the protein. A yeast two‐hybrid screen was implemented
using a C‐terminal truncation termed POT1ΔC, retaining the DNA binding domain. This screen yielded a partial cDNA
corresponding to TRIP6, a member of the LIM domain protein family. TRIP6 could co‐immunoprecipitate with POT1, TRF2
and TIN2 in human cells, arguing for association with the whole shelterin complex, and was detected at telomeres by ChIP.
TRIP6 depletion by siRNA led to the induction of telomere dysfunction induced foci (TIFs), indicating a role in telomere
protection. A closely related LIM domain protein, LPP, was also found at telomeres and was also important for repressing
the DNA damage response. We propose that TRIP6 and LPP are both required for telomere protection.

INTRODUCTION

POT1 [1]. TIN2 has the ability to interact with both
TRF1 and TRF2 simultaneously, and additionally
recruits TPP1/POT1 to the complex. The TPP1/POT1
heterodimer is believed to have a dual role in the
regulation of telomerase. POT1 itself is able to prevent
or limit telomere elongation through its DNA binding
activity [4], and TPP1 possesses a recruitment domain
for telomerase providing a link between the enzyme and
the chromosome’s end [5]. It is with two N-terminal OB
folds that POT1 binds the telomeric overhang, with high
affinity and sequence specificity [6, 7].

Telomeres are essential chromosomal elements, which
ensure proper replication and protection of chromosome
ends. Human telomeres are constituted by 2-12 kb of
double-stranded TTAGGG repeats and present a singlestranded overhang of about 150 nucleotides. Telomeres
prevent an inappropriate DNA damage response by
recruiting a six-protein complex called shelterin, which
is able to inhibit the induction of ATM and ATR
responses [1]. They are also part of a feedback loop that
ultimately regulates the ability of telomerase to add
TTAGGG repeats preferentially to short telomeres [2].
Both of these activities require binding of POT1, one of
the shelterin components, to the telomeric overhang [3].

Extensive analysis of the shelterin complex by mass
spectrometry and proteomics, performed by a number of
laboratories [3, 8-10] has led to the discovery of
shelterin as a stable complex of six proteins, and in
some cases, has identified components transiently
associated with telomeres (eg. the MRE11 complex
[11]). However, some other components known to
impact on telomere function, including telomerase

The assembly of shelterin on the telomere is initiated by
TRF1 and TRF2, which bind double stranded TTAGGG
repeats directly through a MYB-type DNA binding
domain. They in turn recruit RAP1, TIN2, TPP1 and
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itself, have been difficult to detect at telomeres by
biochemical methods. These may not be associated with
telomeres throughout the cell cycle, and are recruited
through poorly understood regulatory events. For
instance, the WRN helicase, mutated in the aging
disease Werner syndrome, was shown to associate with
telomeres in S-phase and to participate in lagging strand
DNA synthesis [12]. Thus, some activities, although
only transiently associated with shelterin, may be
important to mediate its role in telomere function. The
currently established shelterin-associated components
are recruited through structurally related domains in
TRF1 and TRF2 by recognition of F/Y-X-L-X-P
docking sites [13]. Another important interaction at the
telomere involves the OB fold of TPP1, proposed to be
important for the recruitment of telomerase at
chromosome ends [5].

complex. The engagement of POT1 with the overhang
is essential for this inhibitory role, because expression
of a N-terminal truncation of the DNA binding domain
leads to extensive telomere elongation [4, 21].
In vitro systems have demonstrated a positive role for
POT1 and the POT1-TPP1 heterodimer in telomerase
activity on a model telomere seed [22]. POT1 by itself
can lead to increased telomerase recruitment depending
on the distance between the binding site and the 3’end
of the DNA. More recently, the POT1-TPP1 dimer has
been shown to increase repeat addition processivity of
the enzyme through a domain in TPP1 [23]. TPP1 itself
has been proposed to directly recruit telomerase to
telomeres through an OB fold present in the molecule
[5]. Therefore, POT1-TPP1 has a dual role in
telomerase regulation: a positive role through
recruitment and enzymatic regulation of the enzyme,
and a negative role through overhang binding activity.
These complex activities of POT1 could be regulated in
vivo by yet unknown factors.

POT1 regulates telomere length through its overhang
binding activity and mediates telomere protection
through inhibition of the checkpoint kinase ATR [1].
POT1 is composed of two functional domains. The first
domain lies in the C terminus, and mediates the
recruitment of POT1 to telomeres through an interaction
with TPP1 [14, 15]. The second domain is the Nterminal DNA binding domain constituted by two OB
folds, responsible for binding the telomeric overhang
with high affinity and sequence specificity [7]. The two
POT1 OB folds span the first 299 amino acids of the
protein [7]. It is through the binding of the telomeric
overhang that POT1 exerts its biological function at
telomeres.

Since the DNA binding domain of POT1 is essential for
both telomere length control and the inhibition of the
DNA damage response at telomeres, protein
associations with this domain are of great interest to
explore. For instance, the roles of POT1 in inhibiting
telomerase and the ATR kinase could be mediated by a
factor that could either modulate the overhang binding
of POT1, or act as a mediator molecule once POT1 has
engaged on the DNA.
In this study, we sought to isolate POT1-associated
factors that interact with the DNA binding domain of
the molecule, therefore expected to play a role in the
function of POT1 and not its recruitment. We employed
the yeast two-hybrid system to discover potential novel
shelterin-associated proteins. To that end, we targeted
the screen for candidates binding to the N-terminal
domain of POT1, containing the two DNA binding OB
folds. We report on the finding that the LIM domain
proteins TRIP6 can interact with the POT1 DNA
binding domain by two-hybrid, an interaction that we
confirmed in human cells. TRIP6, initially identified as
a Thyroid Receptor Interacting Protein, met the criterion
of binding specifically the N-terminus of POT1 by yeast
two-hybrid analysis, and can be detected in a complex
with POT1 and other shelterin components in human
cells. TRIP6 was previously implicated in cytoskeletal
rearrangements and in transcriptional control [24]. LIM
domains are known protein interaction domains that
present distinctive loops defined by interactions
between Cys and His residues coordinating a Zn ion,
and define a family of proteins subdivided in specifics
groups (reviewed in [25]). Our data is compatible with

The DNA binding activity of POT1 was shown, in the
mouse conditional knock out system, to mediate
repression of the ATR kinase [16, 17], itself an
important component of the DNA damage response.
This response, which is detected upon the removal of
POT1 in mouse cells, results in the convergence and
accumulation of DNA damage proteins at telomeres,
which are in this case “sensed” as damaged DNA. For
instance, DNA damage proteins p53BP1, γH2AX [18],
and MDC1 [19] can be detected as foci co-localizing
with telomeres. Ultimately, telomere deprotection can
lead to extensive end-to-end telomere fusions, a
catastrophic cellular event. The initial convergence of
proteins involved in the DNA damage response at
telomeres leads to the formation of TIFs, (telomere
dysfunction-induced foci).
Another important role for POT1 is the cis-inhibition of
telomerase. Depletion of POT1 by siRNA leads to
elongation of telomeres in telomerase-positive cells
[20], placing POT1 in a cis-inhibiting pathway of
inhibition of telomerase as a part of the shelterin
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TRIP6 being transiently associated with telomeres, an
association which is readily detected by chromatin
immunoprecipitation. We report that the closely related
LIM protein LPP was also found in a complex with
shelterin components. We found that single depletion of
TRIP6 or LPP leads to TIF formation detected by
accumulation of p53BP1 at telomeres. Based on our
results, we propose that TRIP6 and LPP are both
important for telomere protection.

RESULTS
Choice of the POT1 bait and yeast two-hybrid screen
In order to specifically screen for proteins that associate
with the DNA binding domain of POT1, we constructed
an allele predicted to contain the full OB fold necessary
for DNA binding, but with a truncated TPP1 interacting
domain. The locations of these domains have been
extensively described and mapped [7, 15, 17]. The
POT1 allele we constructed, termed POT1∆C, contains
the first 379 amino acids of the protein, with a full
DNA-binding domain as described in [7], with an
additional 79 amino acids, but not the TPP1-binding
domain, located in the C-terminal region [15].
Therefore, POT1∆C should be unable to quantitatively
associate with telomeres but retain full DNA binding
activity. Introduction of a MYC-tagged version of
POT1∆C by retroviral transduction in HTC75 cells
showed that this allele was expressed at significantly
lower levels than full-length POT1 (1A, left). This was
also observed in the context of a fusion with GFP,
where GFP-POT1∆C showed lower levels than the
GFP-POT1 wild-type fusion (Figure 1A, right). Despite
low levels of expression, the GFP-tagged NLSPOT1∆C construct allowed us to assess the intranuclear
localization of the protein. As predicted, and unlike fulllength GFP-POT1, GFP-POT1∆C failed to accumulate
to telomeres, but instead showed a diffuse nuclear
pattern (Figure 1C). A GST-POT1∆C construct was
made that allowed us to perform in vitro DNA binding
assays. We found that the binding affinity of GSTPOT1∆C was indistinguishable from that of the fulllength protein (Figure1B). Therefore, the POT1∆C
allele represents a segment of POT1 with a full DNA
binding domain, suitable for expression in yeast as a
two-hybrid bait. The screen was expected to yield
clones that associate with the DNA binding domain of
POT1, and to exclude TPP1, which interacts with the Cterminus of the molecule [15].

Figure 1. Localization and DNA binding activity of the
∆C

POT1 allele. (A) Expression levels of MYC‐or GFP‐tagged
alleles in HTC75 cells. The full‐length (FL, 71kD), POT1∆OB (∆OB,
MW 57kD) and POT1∆C(∆C, MW 43kD) are shown along a
vector‐only control. Blots probed with the 9E10 (anti‐MYC) (left)
or 978 (anti‐POT1) antibodies (right) are shown. (B) Gel shift
32
assay for GST‐POT1 and GST‐POT1∆C. A P‐labelled oligonucleo‐
tide containing the POT1 minimal binding site was incubated
with the amounts of GST fusion protein shown on top. The free
probe is visible at the bottom of the autoradiogram. (C)
Intranuclear localization of GFP‐NLS‐POT1 and GFP‐NLS‐POT1∆C.
The GFP‐tagged protein is detected in the FITC channel (left),
and telomeres are stained with an anti‐TRF1 antibody (371,
middle panels). The overlay is shown in the right panels.

3 plasmids were recovered that conferred robust His+
and LacZ+ phenotypes upon re-transformation (Figure
2A). During the retests, plasmids containing TRF1GAD, TRF2-GAD (Figure 2A, 2B) and RAP1-GAD

The yeast two-hybrid screen was performed with LexAPOT1∆C as a bait, in the L40 yeast strain, with the
LacZ and HIS3 genes as reporters. After initial screening of 2x106 transformants and subsequent retesting,
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(not shown), all fusions that were analyzed in separate
studies in the L40 strain [26] [27], were also tested
against the LexA-POT1∆C bait and showed no
activation, demonstrating the specificity of the
interaction for the bait. All three recovered clones
corresponded to the 3’ half of the same cDNA,
containing the three C-terminal LIM domains of TRIP6
in fusion with the GAL4 activation domain at amino
acid 218. Tests performed in yeast confirmed that the
clones interacted with full-length POT1 (Figure 2B),
showing that the interaction detected in yeast was not an
artifact of the truncation of the protein. The activation
of LacZ was evident with both POT1∆C and full length
POT1, although in the latter case some background
activation of the promoter occurred without the prey
(Figure 2B). We also tested the library clone obtained
against other LexA fusions such as LexA-TRF1 (Figure
2B), showing that the TRIP6 fusion had specificity for
the POT1 bait. Altogether, the results from the two-hyb-

rid screen argue for an interaction between the Nterminal domain of POT1 and the C-terminal LIM
domains of TRIP6. A POT1∆OB fused to LexA
construct was also tested against the TRIP6 fragment, in
order to ask whether the interaction was lost when the
first OB fold is absent. In this case, the high LacZ+ and
His+ background caused by POT1∆OB alone precluded
the analysis. TRIP6 was isolated previously as one of
the thyroid receptor interacting molecules and was later
characterized as binding to adhesion plaques. A role for
organizing the actin cytoskeleton at adhesion plaques
has been established [28], and nuclear roles for the
protein have been described [29, 30]. The molecule has
a molecular weight of 60kD and can be divided into two
roughly equivalent regions: an N-terminal half,
containing a nuclear export sequence, referred to as the
pre-LIM domain, and a C-terminal half with three
predicted LIM domains. It is the latter region of TRIP6
which was isolated in the screen.

Figure 2. The LIM domains of TRIP6 interact with POT1∆C by yeast two‐hybrid. (A) Top: His phenotypes of the B40 strain
carrying the pLexA‐POT1∆C bait plasmid and the plasmids shown on the right side, including the b12 positive clone and another
recovered clone, c3, which proved negative upon retransformation. Bottom: Patch LacZ assay of the same strains, showing that the
b12 clone activates the LacZ reporter gene as well. (B) Liquid β‐Gal assays using the B40 yeast strain and the bait plasmids shown at
the bottom, with the GAD vector or GAD‐b2 clone. The b2 clone activates LacZ with LexA‐POT1 or LexA‐POT1∆C, but not with LexA‐
TRF1. The standard deviations were calculated on three independent yeast colonies, each assayed three times.
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possible, although not demonstrated here, that the first
OB fold of POT1, which is missing in POT1∆OB, is
necessary for the interaction. We also used MYCPOT1∆C in this assay. Owing to the low expression of
the protein (see above), we could not detect an
association with TRIP6 in this case. However, a
stabilization of MYC-POT1∆C upon co-transfection
with FLAG-TRIP6 was observed (not shown),
compatible with an interaction between the two
proteins.
A MYC-tagged TRIP6 cDNA was stably introduced by
retroviral transduction into HTC75 cells, in order to
further the co-immunoprecipitation analysis and to
study the localization of the protein by
immunofluorescence. In MYC-TRIP6 expressing cells,
a weak but reproducible signal was detected after
immunoprecipitation with two independent anti-POT1
sera (Figure 4A). This confirmed that the interaction
detected by yeast two hybrid and transient transfection
was detectable in stably expressing cells. We then
explored whether TRIP6 could be pulled down with
antibodies against other shelterin components. A very
robust precipitation of TRIP6 was observed with an
anti¬TRF2 antibody (Figure 4A). TRIP6 could also be
pulled down with TIN2 antibodies (Figure 4A). Because
TRIP6 could be pulled down by antibodies to several
shelterin components, our results argue for an
association between TRIP6 and the whole complex. We
cannot rule out a direct interaction between TRIP6 and
other shelterin components, such as TRF2, that are not
detected by the yeast two-hybrid tests. The cellular
localization of TRIP6 in our established cell lines was
seen as mostly cytosolic staining, as previously
described by others (SS and DL, unpublished, and [30]).
We found no evidence for telomeric localization by
immunofluorescence. We reasoned that accumulating
TRIP6 in the nucleus might increase the signal detected
in the co-immunoprecipitation experiments. To test this,
we generated an allele of TRIP6 with an inactivated
NES (the allele described in [30]), named TRIP6-NES .
We confirmed by immunofluorescence that this mutant
allele accumulated in the nucleus. No difference was
observed in the coprecipitation between POT1 or TRF2
and wild-type or TRIP6-NES (not shown). It is possible
that the interaction between TRIP6 and shelterin is
highly regulated and not driven by high nuclear
amounts of the protein.

Figure 3. POT1 interacts with TRIP6 in transient
transfections. (A) IP‐Western blots on lysates made from
transiently transfected 293T cells, to detect co‐
immunoprecipitation of the transfected proteins. MYC‐POT1
was co¬transfected with FLAG‐TRIP6 or with the FLAG vector,
and the lysates were used for immunoprecipitations with the
9E10 (anti‐MYC) or M2 (anti‐FLAG) antibodies, as shown on top.
A Total fraction (TOT) and beads only control (B) were run
alongside. The blot was probed with the 9E10 antibody, and the
position of MYC‐POT1 is indicated by the arrow. The
immunoprecipitated MYC¬POT1 by the FLAG antibody is shown
with the black triangle. (B) Same as A, except that MYC‐
POT1∆OB is used in the co‐transfection.

Cloning and expression of the full-length human
TRIP6 cDNA
The full-length TRIP6 cDNA was obtained as an EST
and cloned into a retroviral mammalian expression
vector (pLPC) in fusion with a FLAG or MYC epitope
tag, in order to express the tagged full-length cDNA in
human cells. We sought first to confirm the interaction
between POT1 and TRIP6 detected in yeast. Transient
co-transfections in 293T cells with full-length POT1,
POT1∆C or POT1∆OB were performed to ask whether
MYC-POT1 could coimmunoprecipitate specifically
with FLAG-TRIP6. We found that TRIP6 could pull
down full-length POT1 (Figure3A). In addition, cotransfection of TRIP6 resulted in the stabilization of
POT1. Both these observations suggest an interaction
between full-length TRIP6 and POT1. No interaction or
stabilization was detected with POT1∆OB (Figure3B),
suggesting, in conformity with the setup of the yeast
two-hybrid screen, that the N-terminal OB folds are
important for the POT1-TRIP6 interaction. It is
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LPP, closely related to TRIP6, also interacts with
shelterin
In our analysis of TRIP6, we noted that the human
genome encodes a highly related protein called LPP,
which, as TRIP6, is part of the Zyxin family. The
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homology in the C-terminal LIM domains between
TRIP6 and LPP is very high: the sequence identity
between the two in the first LIM domain is about 60%,
and 77% and 75% for the second and third LIM
domains respectively [31]. The high homology between
the C-termini of TRIP6 and LPP prompted us to
investigate whether LPP also associated with shelterin.
Although the degree of identity is lower in the Nterminal third of the protein (around 35%), the overall
domain structure is identical between LPP and TRIP6,
with, notably, a nuclear export sequence arguing for
active shuttling of LPP between cytoplasm and nucleus.
Based on the degree of homology and domain structure
of the two molecules, it is possible that TRIP6 and LPP
share an ability to interact with shelterin. The fulllength LPP cDNA was cloned into pLPC-MYC and
stably expressing cell lines were obtained in HTC75. By
IP-Western, MYC-LPP was found to co-precipitate with
POT1, TRF2, TRF1 or TIN2 antibodies (Figure 4B).

Therefore, LPP could associate with shelterin as well.
This shared ability with TRIP6 to be in a complex with
shelterin could be mediated by the highly similar Cterminal LIM domains, although the interaction
domains in TRIP6 and LPP remain to be defined.
TRIP6 and LPP can be detected at telomeres by
chromatin immunoprecipitation
Immunofluorescence analysis of TRIP6 or LPP
localization yielded results in accordance with a
previously published report [30]: the pattern displayed
cytoplasmic staining compatible with a much higher
concentration of TRIP6 and LPP in the cytoplasm than
in the nucleus. We confirmed the published observation
that TRIP6 or LPP could accumulate in the nucleus
upon treatment with Leptomycin B supporting the
notion that they both actively shuttle between nucleus
and cytoplasm (SS and DL, unpublished).

Figure 4. TRIP6 and LPP co‐immunoprecipitate with several shelterin components. (A) IP‐Western blots
on lysates made from HTC75 cells obtained through retroviral transduction, stably expressing MYC‐TRIP6 (50kD)
(the vector only control is shown on the left). The lysates were used for immunoprecipitations with the antibodies
listed on top, and analyzed for the amounts of MYC‐TRIP6 by Western blot with the 9E10 antibody. The Total
fraction was ran alongside as indicated. The POT1 sera were the anti‐epitope #4955 (left panel), and the
anti¬baculovirus POT1 #1048 (right panel). (B) Same as A, as with a MYC‐LPP (66kD) expressing HTC75 cells.
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Figure 5. TRIP6 and LPP are detected at telomeres by ChIP. (A) Chromatin immunoprecipitations with
fixed lysates prepared from HTC75 cell lines indicated on the left. The antibodies used are listed on top
(I=Immune, PI=PreImmune), and the Total DNA fraction is on the right side of each blot as indicated. Extracted
DNA samples were dot‐blotted on Nitrocellulose, and probed with a TTAGGG probe (top), or with an Alu probe
(bottom) as a control. The yields calculated for the samples probed with Alu were all below 0.5%. (B) Histogram of
the values for the yields as % of total DNA of the samples shown in A.

In order to address whether TRIP6 or LPP associate
with shelterin at telomeres, we turned to the chromatin
immunoprecipitation (ChIP) technique. This technique
has been extensively used to study the presence of
shelterin components or other proteins on telomeric
DNA. Anti-peptide rabbit sera against TRIP6 or LPP
were used for this analysis, which were both raised
against epitopes in the N-terminus which were
significantly divergent between the two proteins. We
confirmed that the TRIP6 and LPP sera were competent
for immunoprecipitations and not crossreacting (Figure
S2). In asynchronous HTC75 cells, TRIP6 was found to
associate with telomeres with a yield of about 5% of
total TTAGGG DNA (Figure 5A,5B), about half the
yield seen for POT1 in this assay and comparable with
the yield obtained for TPP1. TRF1 antibodies, used as a
control here, pulled down 20% of total telomeric
sequences, in accordance with previously published
results [4]. LPP could also be detected at telomeres by
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ChIP (Figure 5A). The yield for LPP was 3.5% of total
DNA, in the same range as TRIP6. The yields for Alu
sequences, used her as internal control sequences, was
between 0.5 and 1% for all samples. These results show
that the interactions between TRIP6 or LPP and
shelterin are taking place at the telomere and likely
reflect a role for these LIM-domain proteins in telomere
function. Thus, both TRIP6 and LPP are found at
telomeres in asynchronously growing HTC75 cells.
We also probed the telomeric association of TRIP6 and
LPP by ChIP in cells expressing POT1∆OB . These
cells have highly elongated telomeres, concomitant with
a lower expression of endogenous full-length POT1 [4].
We found that TRIP6 or LPP show a yield similar to
that observed in non-expressing HTC75 cells (ca 5%)
(Figure 5A, 5B), which results in a stronger signal on
the dot-blot (Figure 5A) due to the significantly longer
telomeres in POT1∆OB cells. Such a pattern is observed
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for other telomeric or telomere-associated proteins such
as TRF1 (see Figure 5A), POT1, RAP1 or MRE11, and
is evidence for association with the overall telomeric
chromatin [4]. Therefore, it appears that TRIP6 and LPP
associate with shelterin along the whole telomere. Also,
the strong depletion of full length, endogenous POT1 in
POT1∆OB cells [4] does not lead to a disappearance of
TRIP6 or LPP from telomeres, suggesting that the OB
folds of POT1 are not involved in recruiting TRIP6 or
LPP to telomeres, which would then occur through
other events or interactions to be defined. Thus, the
interaction between the LIM domains of TRIP6 and the
N-terminus of POT1 is not expected to mediate the
recruitment of TRIP6, but rather to be relevant to the
function of the protein. Whether the same holds true for
LPP remains to be determined, but the high homology
between the LIM domains of LPP and TRIP6 suggest
that they both are able to interact with the POT1 Nterminus. The modalities of recruitment of TRIP6 and
LPP to telomeres are interesting questions to pursue.

increase over background, detected in the GFP siRNA
control.
We observed similar results with the siRNA depletion
of LPP. In this case also, an overall increase of p53BP1
was evident, from 1 to 1.8 foci per nucleus, arguing for
a role in general repression of a DNA damage response
in these cells. The degree of TIF formation was similar,
but slightly lower, to that observed with TRIP6, with
32% of the cells showing 3 or more foci co-localizing
with TRF2, a two-fold increase over background. Since
depletion of either TRIP6 or LPP alone led to a DNA
damage response at telomeres, we conclude that both
are necessary to fully protect telomeres, possibly by
cooperating with POT1.

DISCUSSION
In this study, we describe a novel association between
shelterin and LIM domain proteins at telomeres. These
are the LIM-domain proteins TRIP6 and LPP, two
related molecules of the Zyxin family [25]. We first
identified TRIP6 in a two-hybrid screen for proteins that
associate with the DNA binding domain of POT1.
Binding to POT1 and the shelterin complex could have
two significant consequences: the recruitment of the
protein to telomeres, and a role in telomere function.
Given that the DNA binding domain of POT1 mediates
the function of the protein in protection and length
regulation [1], and that TRIP6 and LPP recruitment are
not affected by high expression of POT1∆OB, we argue
that the interaction between POT1 and TRIP6 detected
in yeast relates to function and not recruitment. It
remains to be determined how and when TRIP6 and
LPP are recruited to telomeres.

TRIP6 and LPP are involved in telomere protection
To analyze the possible roles of TRIP6 and LPP in
telomere function we first examined telomere length in
HTC75 cells over 60 population doublings in cells
overexpressing either TRIP6 or LPP. The impact of
shelterin components depletion or overexpression is
normally detected during this span, but no effect was
observed for TRIP6 or LPP (data not shown). We then
turned to the analysis of TRIP6 or LPP siRNA depletion
on telomere protection in HTC75 cells.
We analyzed the possible short-term effects (48hr post
transfection) of TRIP6 or LPP depletion on the
induction of a DNA damage response at telomere. Such
a response can be monitored by the induction of
p53BP1 foci that partially co-localize with telomeres,
indicative of telomere de-protection [18,32]. For siRNA
of TRIP6 or LPP, we used targets sites that led to partial
depletion of exogenous MYC-TRIP6 or MYC¬LPP as
observed by Western blot (Figure S1). The depletion of
TRIP6 led to a significant increase of p53BP1 foci in
the nuclei, suggestive of an induction of a DNA damage
response a numerous sites in the genome. The number
of p53BP1 nuclear foci increased from an average of 1
to 2.65 per nucleus, including untransfected cells which
tend to lower the number in this case. In particular, we
observed the induction of telomere dysfunction induced
foci (TIFs), as observed by the formation of p53BP1
foci that co-localized with TRF2 (Figure 6). Upon
depletion of TRIP6, 40% of the nuclei showed 3 or
more p53BP1 foci co-localizing with TRF2, indicating
that some of these foci represented a DNA damage
response at telomeres. This value represented a 2.7-fold

www.impactaging.com

The LIM superfamily of proteins contains at least 50
members in the human proteome and is subdivided into
seven families, all made of proteins with predicted LIM
domains in various arrangements [25]. TRIP6 is part of
the Zyxin family, along with other members such as
LPP or Ajuba, characterized by the presence of three
LIM domains at the C-terminus of the molecule.
However, intriguingly, these molecules possess a
nuclear export sequence, which accounts for their active
shuttling between the nucleus and the cytoplasm. A
nuclear role for TRIP6 as a transcription factor has
been described [29, 30], arguing for an important role
for this molecule in addition to that performed in the
cytoplasm.
TRIP6 and LPP are not detected at telomeres by
immunofluorescence, and, instead, show a cytoplasmic
localization pattern seemingly at odds with a role in the
nucleus and at telomeres (DL and SS, unpublished, and
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[30]). However, they are known to shuttle actively
between the cytoplasm and the nucleus, in a manner
dependent on the NES present in the N-terminal half of
the molecule [30]. The telomeric association we detect
is therefore probably not representative of the majority
of the cells in the population, but rather occurs in a
minority of the cells experiencing high TRIP6/LPP nuc-

lear concentration. Although this remains to be
established, it would be interesting to investigate an
accumulation of TRIP6 and LPP at telomeres during Sphase, a period in the cell cycle with high demand for
protective activities [33]. As such, TRIP6 and LPP
would be active only transiently at telomeres, perhaps
during DNA replication.

Figure 6. Depletion of TRIP6 or LPP leads to TIF formation. (A) Immunofluorescence showing
the intranuclear localization of p53BP1 in TRIP6¬depleted HTC75 cells (middle panels), LPP‐depleted
cells (right panels) or control siRNA (GFP, left). The detected fluorescence (DAPI, FITC for TRF2,
TRITC for p53BP1) is indicated on the left, and white triangle point to the co¬localized TRF2‐p53BP1
foci. (B) Histogram of the values for co‐localized p53BP1 and TRF2 foci (left, greater than 3, right,
greater than 5 per nucleus) as a percent of the total nuclei counted. 100 nuclei were counted for
each set, and the standard deviations were calculated on three separate experiments.
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The roles of TRIP6 and LPP could impact on two main
processes: either telomere protection or telomere length
regulation through the control of telomerase. Our results
suggest that TRIP6 and LPP both individually
contribute to the protection of telomeres, in preventing
the damage response otherwise elicited through
activation of ATM or ATR pathways. An impact for
TRIP6 or LPP on telomere length regulation has not
been detected but is still under investigation. The high
sequence similarity between TRIP6 and LPP likely
accounts for their recruitment to telomeres, possibly
through a common pathway, although our data argue
that each individually is important for proper telomere
protection.

strain bears the HIS3 and LacZ reporter genes under the
control of the LexA DNA binding site. The libraries
used were the HeLa S3 or the human testis matchmaker
cDNA library (Clontech), containing random fusions to
the GAL4 activation domain. The TRIP6 two-hybrid
cDNA clones (aa positions) containing the three LIM
domains of the molecule where isolated and retransformed into the L40 containing the bait to ensure
that the His+ and LacZ+ phenotypes were due to the
library plasmid.
Two-hybrid assays. The two-hybrid tests shown in
Figure 2 were performed also in the L40 strain with the
LexA-TRIP6 full length cloned in pBTM116 (Bartel et
al., 1993) by PCR of the TRIP6 EST (see below) and
tested against a number of previously characterized and
published fusions with the GAL4 activation domain:
TRF1-GAD, TRF2-GAD, and POT1¬GAD, all cloned
into the pACT2 vector (Clontech). The BGal liquid
assays were performed as described in the Clontech
Matchmaker protocol and three independent colonies
were assayed for each plasmid combination, and the
standard deviations reported are based on three separate
experiments.

A nuclear role for LIM proteins, in particular in the
Zyxin family, has been established previously. Like
TRIP6, the protein Ajuba, has an NES as well as three
C-terminal LIM domains. Ajuba was found to associate
with kinetochores and to participate in the spindle
assembly checkpoint [34]. Also, Ajuba was found to corepress transcription at RAREs through interactions
with, among other factors, RARα. The mechanism of
co¬repression was found to occur through recruitment
of PMRT5, an Arginine methylase whose enzymatic
activity was found to be essential in this process [35]. In
this context, the LIM domains of Ajuba constitute a
platform of interactions to mediate transcriptional
repression through Arginine methylation. Interestingly,
Ajuba shares the ability to interact with RARα with two
other Zyxin family members, WTIP and LimD1, while
TRIP6 and LPP are negative in this assay [35]. This
observation parallels ours, in that more than one LIM
protein can play a role in the same process. We find it
tempting to speculate that TRIP6 and LPP bring similar
activities to the telomeres, as Ajuba and WTIP do to
RAREs, in recruiting for instance an Arginine
methylase. Arginine methylation of TRF2, a shelterin
component, has recently been implicated in telomere
function, in particular in repressing premature sensecence in primary cells [36]. Therefore, there might be a
subdivision in the Zyxin family, some members being
involved in transcriptional repression, and others in
telomere protection. Further work will determine
whether the activities of TRIP6 and LPP at telomeres
are important for the repression of the senescence pathway under the control of shelterin, in particular TRF2.

Cell lines and antibodies. The HTC75 cell line is a
HT1080 derivative described in [37]. The cells were
grown in DMEM/10%BCS, and the retroviral
transduction protocol was identical to that described in
[38]. The antibodies against TRIP6 and LPP were
generated against a peptide conjugated to KLH and used
for immunization into rabbits, as per the protocol set by
the manufacturer (BioSynthesis, Lewisville, TX). The
peptides were: NH2-GCPKKFAPVVAPKPKYNPYKQ
-OH for LPP, and GC-LNGGRGHASRRPDRQAYEOH for TRIP6. The TRF2 antibodies were the 647
against the full-length protein made in Sf9 cells [11], or
the anti-peptide 508 [39]; the TRF1 antibody was the
anti-peptide 371 [37]; the POT1 antibodies were the
1048 against the full-length protein made in Sf9 cells or
the anti-peptide 978 [4]; and the Tin2 antibodies were
the 864 made against the full-length protein in Sf9 cells
[40]. The p53BP1 antibody was purchased from Novus
(NB100-304).
Plasmids. The TRIP6 and LPP cDNAs were purchased
as full length clones from the EST collection maintained
by the ATCC (TRIP6) or Invitrogen (LPP). The full
length cDNAs were amplified by PCR using primers
with appropriate cloning sites (5’ Bgl II and 3’ Xho I)
and cloned into pLPC-MYC [38] to generate a MYC
tagged version driven by the CMV promoter. The PCR
oligonucleotides were: 5’ AGATCTTCGGGGCCCACC
TGGCTGCCCCCG and 5’CTCGAGTCAGCAGTCAG
TGGTGACGGTGGC for TRIP6, and 5’ AGATCTCA

MATERIALS AND METHODS
Two-hybrid screen/Isolation of TRIP6. A two-hybrid
screen was carried out with the yeast reporter strain L40
(Hollenberg et al., 1995; Bianchi et al., 1997), using the
human POT1∆C C-terminal truncation (aa 1-379) fused
to the LexA DNA binding domain as a bait. The L40
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CCCATCTTGGC and 5’ GAGTCTGAGCTAAAGGT
CAGT for LPP.

Immunoresearch) in PBG at a concentration of 1:1000
for 45 min at RT. Cover slips were rinsed two times
with PBG. Coverslips were then incubated with PBG
and 4=,6=-diamidino-2-phenylindole (DAPI) at 100
ng/ml to visualize the nuclei. Coverslips were mounted
on to slides with embedding media. Images were
collected with an Olympus BX61 fluorescence
microscope using a 60X objective connected to a
Hamamatsu ORCA-ER CCD camera, controlled by the
SlideBook 5.1 image capture software.

The POT1∆OB construct is described in [4], and the
POT1∆C construct was cloned by PCR-cloning of
amino acids 1-379 of POT1 into pLPC-MYC for
expression into human cells, or pBTM116 to use as a
bait for the two-hybrid screen. The POT1 and POT1∆C
fusion with eGFP where performed using a vector
constructed with the eGFP fragment from the pEGFPC1 vector (Clontech) subcloned into pBabe-Puro. An
NLS was cloned as a BamHI fragment into the BglII
site of the polylinker, and the full-length POT1 or
POT1∆C fragments were cloned as BamHI-XhoI
fragments downstream of the NLS, generating Nterminally GFP-tagged protein fusions actively
transported into the nucleus.

Chromatin immunoprecipitations. The chromatin immunoprecipitations were performed as described in [4].
E.coli GST-POT1 and bandshift assays. The purification protocol is detailed in [41], and the bandshift assays
were performed as described in [6].

RNA interference. HTC75 cells were maintained in
DMEM (Invitrogen) supplemented with 1% penicillin
and streptomycin and 10% fetal bovine serum (FBS).
TRIP6, and LPP-specific siRNAs were synthesized by
Dharmacon RNA Technologies. For TRIP6 RNAi,
double-stranded siRNA were designed to target the
following sequences: TRIP6(6.1)siRNA 5’-AGGAGGA
GACUGUGAGAAUUU-3’ TRIP6(6.2)siRNA 5’CUGGAUAGGCUGACGAAGAUU-3’ LPPsiRNA(L.1)
5’CUCAUAAUGUGAAAUAUGA¬3’ LPPsiRNA(L.2)
5’GCCAUUCUAUGCUGUGGAA-3’ HTC75 cells
were transfected using Lipofectamine (Invitrogen)
according to the manufacturer’s instructions. Briefly,
cells at a confluency of approximately 50-60% were
plated in a 6-well plate 18-24 hr prior to transfection.
Transfections were done one time within a 24 hr
interval and cells were processed 48 hr after the first
transfection. As a control, siRNA designed to target
GFP (Dharmacon) was used.
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SUPPLEMENTAL FIGURES

Figure S1. Depletion of TRIP6 or LPP by siRNA. Western blot of lysates prepared from MYC‐
TRIP6 or MYC‐LPP expressing cells transfected with the siRNA indicated on top, with the anti‐MYC
9E10 antibody as a probe. The siRNA 6.2 was used for TRIP6 depletion, and P.1 for LPP depletion.

Figure S2. The anti‐TRIP6 or LPP sera are proficient for immunoprecipitations. IP‐Western
blots showing that the rabbit TRIP6 antibodies (5023) or LPP antibodies (6073,6074) are able to
immunoprecipitate MYC‐TRIP6 or MYC‐LPP, with the preimmune sera (PI) as negative controls. The
TRIP6 sera did not precipitate LPP, and the LPP sera did not precipitate TRIP6.
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